Durvalumab (Imfinzi) and Rintatolimod (Ampligen) — Clinical data readout
Q1 2027
We anticipate DURIPANC data on clinical benefit in Q1 2027 and on Overall Survival – the gold standard data point in oncology – in Q3 2027.Source filing
AIM biotech catalysts & pipeline
AIM IMMUNOTECH INC · Data as of 2026-10-25
Upcoming catalysts
Durvalumab (Imfinzi) and Rintatolimod (Ampligen) — Clinical data readout
Q3 2027
We anticipate DURIPANC data on clinical benefit in Q1 2027 and on Overall Survival – the gold standard data point in oncology – in Q3 2027.Source filing
Durvalumab (Imfinzi) and Rintatolimod (Ampligen) — Conference presentation
2026
Erasmus MC expects that detailed data will be published later this year.Source filing